GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (STU:296) » Definitions » YoY Rev. per Sh. Growth

CytoDyn (STU:296) YoY Rev. per Sh. Growth : 0.00% (As of Feb. 2025)


View and export this data going back to 2016. Start your Free Trial

What is CytoDyn YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. CytoDyn's YoY Rev. per Sh. Growth for the quarter that ended in Feb. 2025 was 0.00%.

CytoDyn's Revenue per Share for the three months ended in Feb. 2025 was €0.00.

CytoDyn YoY Rev. per Sh. Growth Historical Data

The historical data trend for CytoDyn's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn YoY Rev. per Sh. Growth Chart

CytoDyn Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CytoDyn Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CytoDyn YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

CytoDyn's YoY Rev. per Sh. Growth for the fiscal year that ended in May. 2024 is calculated as:

YoY Rev. per Sh. Growth (A: May. 2024 )
=(Revenue per Share (A: May. 2024 )-Revenue per Share (A: May. 2023 ))/ | Revenue per Share (A: May. 2023 ) |
=(0-0)/ | 0 |
=N/A %

CytoDyn's YoY Rev. per Sh. Growth for the quarter that ended in Feb. 2025 is calculated as:

YoY Rev. per Sh. Growth (Q: Feb. 2025 )
=(Revenue per Share (Q: Feb. 2025 )-Revenue per Share (Q: Feb. 2024 )) / | Revenue per Share (Q: Feb. 2024 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of CytoDyn's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoDyn Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (STU:296) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
PHAT SEPN ITOS XOMA PVLA ATAI ATXS MRVI ATYR AURA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
CYDY:USA
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
Website
https://www.cytodyn.com
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

CytoDyn Headlines

No Headlines